Wayne Gatlin

机构：Kala Pharmaceuticals (United States)

发表论文 6 篇 · 总被引 101 次 · h-index 3

代表论文

• Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment (2023 · Cell Reports · 被引 94)
• Siglec-engaging immunosuppressive sialoglycans are upregulated in prostate cancer and are targetable to suppress bone metastasis (2025 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 3)
• Abstract LB221: Development of PD-L1-targeted sialidase as a novel cancer immunotherapeutic approach (2022 · Cancer Research · 被引 3)
• Abstract 7158: Human sialidase-armed anti-B7-H3 antibody that enhances innate and adaptive antitumor immune responses (2026 · Cancer Research · 被引 1)
• 1438 Stromal hypersialylation within colorectal tumors contributes to immunosuppression of T cell adaptive immunity in the tumor microenvironment (2023 · Regular and Young Investigator Award Abstracts)
• Abstract LB-109: A novel therapeutic modality of inhibiting the glyco-immune checkpoint axis to treat cancer (2019 · Experimental and Molecular Therapeutics)